Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$20.11 USD
-0.59 (-2.85%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $20.07 -0.04 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Syndax Pharmaceuticals, Inc. [SNDX]
Reports for Purchase
Showing records 21 - 40 ( 48 total )
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Revumenib Receives FDA Breakthrough Therapy Designation; Axatilimab Data Published
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Updated AUGMENT-101 Data in ASH Abstracts
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Data From Pivotal Studies of Revumenib and Axatilimab Expected in 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; One or More AUGMENT-101 Pivotal Cohorts to Complete Enrollment in 2022; AGAVE-201 Trial Data Expected 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Two Potential NDA Filings in 2023; Initiating Coverage With a Buy Rating and $31 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
E2112 Primary Endpoint Missed; Downgrade to Neutral; Lower PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Final Countdown to Phase 3 E2112 Data; Raising PT to $25 on SNDX-5613 Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Initial SNDX-5613 Data at AACR; Raising PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SNDX-5613 Granted Orphan Drug Designation in AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Common Stock Offering and Debt Deal Announced; Reiterating Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Management Provides 2020 Corporate Update; Raising PT to $17 from $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Expansion Cohort for SNDX-6352 Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Entinostat Phase 3 OS Data Expected 2Q20; SNDX-5613 Enters the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
E2112 Trial Passed Final Interim Analysis for OS, Now Looking to 2Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; E2112 OS Analysis Expected in 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clears IND Application for Phase 1/2 Trial of SNDX-5613
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Fourth Interim Analysis for Overall Survival Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E